AbioCor Implantable Replacement Heart Procedure Performed At St. Luke's Episcopal Hospital, Home of the Texas Heart Institute.

Business/Technology Editors & Health/Medical Writers

DANVERS, Mass.--(BUSINESS WIRE)--Sept. 26, 2001

ABIOMED, Inc. (NASDAQ: ABMD) confirmed today that the Houston-based AbioCor(TM) (pronounced "AB'-EE-O-KOR") clinical and research team, led by Drs. O.H. (Bud) Frazier, performed today the world's third implantation of ABIOMED's AbioCor Implantable Replacement Heart at St. Luke's Episcopal Hospital, home of the Texas Heart Institute in Houston, Texas. The procedure conducted today went as expected and the patient is resting comfortably, according to the Hospital.

Consistent with the previously announced policy governing the AbioCor clinical trial, additional information will be made available at a later date to be determined by the medical team and the patient's family. This is consistent with the Company's "quiet period" policy intended to protect patient confidentiality and allow for the best possible medical care.

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's first generation AbioCor Implantable Replacement Heart is being implanted in selected patients as part of an initial clinical trial conducted under an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA). The AbioCor has not been approved for commercial

distribution, and is not available for use or sale outside of the initial clinical trial. ABIOMED currently manufactures and sells the BVS, a heart assist advice for the temporary support of all patients with failing but potentially recoverable hearts.

World-renowned cardiovascular surgeon Denton A. Cooley, MD, founded the Texas Heart Institute in 1962 for the study and treatment of diseases of the heart and blood vessels. Together with the Institute's clinical partner, St. Luke's Episcopal Hospital, it has been ranked among the nation's top ten heart centers in an annual survey published by U.S.News & World Report for the past eleven years.

St. Luke's was founded in 1954 by the Episcopal Diocese of Texas. St. Luke's is home to the world-renowned Texas Heart Institute, founded in 1962. In 2001, St. Luke's earned the Magnet designation, the highest honor in patient care. It is the first hospital in Texas and the southwest to be so honored.

This Release contains references to clinical trials for the AbioCor. Clinical trials are subject to significant risks. ABIOMED's actual results may differ materially from those anticipated for the clinical trials based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks detailed in the Company's filings with the Securities and Exchange Commission. Investors are encouraged to consider these risks and cautioned not to place undue reliance on any forward-looking statements regarding these clinical trials.